CRISM Therapeutics (CRTX) Competitors GBX 11.55 +0.30 (+2.67%) As of 11:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock CRTX vs. JAY, FRG, BHL, KDNC, GROC, ATN, AYM, BEM, JAN, and ORMShould you be buying CRISM Therapeutics stock or one of its competitors? The main competitors of CRISM Therapeutics include Bluejay Mining (JAY), Firering Strategic Minerals (FRG), Bradda Head Lithium (BHL), Cadence Minerals (KDNC), GreenRoc Mining (GROC), Aterian (ATN), Anglesey Mining (AYM), Beowulf Mining (BEM), Jangada Mines (JAN), and Ormonde Mining (ORM). These companies are all part of the "other industrial metals & mining" industry. CRISM Therapeutics vs. Its Competitors Bluejay Mining Firering Strategic Minerals Bradda Head Lithium Cadence Minerals GreenRoc Mining Aterian Anglesey Mining Beowulf Mining Jangada Mines Ormonde Mining Bluejay Mining (LON:JAY) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership. Does the media favor JAY or CRTX? In the previous week, Bluejay Mining had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Bluejay Mining and 0 mentions for CRISM Therapeutics. CRISM Therapeutics' average media sentiment score of 0.00 beat Bluejay Mining's score of -0.48 indicating that CRISM Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bluejay Mining Neutral CRISM Therapeutics Neutral Which has more risk and volatility, JAY or CRTX? Bluejay Mining has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, CRISM Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Which has preferable valuation & earnings, JAY or CRTX? CRISM Therapeutics has higher revenue and earnings than Bluejay Mining. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBluejay Mining-£1.05K0.00-£1.81MN/AN/ACRISM TherapeuticsN/AN/A-£792.20K-£5.81-1.99 Do insiders and institutionals hold more shares of JAY or CRTX? 5.0% of Bluejay Mining shares are owned by institutional investors. 42.3% of Bluejay Mining shares are owned by insiders. Comparatively, 68.8% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is JAY or CRTX more profitable? Bluejay Mining's return on equity of -4.56% beat CRISM Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bluejay MiningN/A -4.56% -8.07% CRISM Therapeutics N/A -13.12%-26.77% SummaryBluejay Mining and CRISM Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get CRISM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON ExchangeMarket Cap£1.26M£1.06B£3.24B£3.02BDividend YieldN/A6.19%5.16%5.02%P/E Ratio-1.99104.03106.08165.88Price / SalesN/A20,765.5428,712,403,950,764,100.00285,131.44Price / CashN/A24.7023.8627.97Price / Book0.277.276.014.46Net Income-£792.20K£71.98M£147.94M£5.90B7 Day Performance-1.03%2.16%0.42%3.82%1 Month Performance-51.06%7.60%5.18%13.76%1 Year PerformanceN/A40.45%26.07%74.29% CRISM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCRISM TherapeuticsN/AGBX 11.55+2.7%N/AN/A£1.26MN/A-1.994Gap DownJAYBluejay MiningN/AN/AN/AN/A£4.98M-£1.05K-12.5813Gap UpHigh Trading VolumeFRGFirering Strategic MineralsN/AGBX 2.19-0.5%N/A-38.0%£4.83MN/A-1.87N/AGap UpBHLBradda Head LithiumN/AGBX 0.98+0.4%N/A-44.8%£4.79MN/A1.65N/AGap UpKDNCCadence MineralsN/AGBX 1.58-1.3%N/A-36.5%£4.58MN/A-0.806Gap DownGROCGreenRoc MiningN/AGBX 2.34+1.7%N/A+24.7%£4.52MN/A-3.036ATNAterianN/AGBX 35.60-5.1%N/AN/A£4.29MN/A-1,899.7322Gap DownAYMAnglesey MiningN/AGBX 0.82+0.4%N/A-15.8%£4.20MN/A-0.012Gap UpBEMBeowulf MiningN/AGBX 10.36-1.4%N/A-58.9%£4.02MN/A-2.1213JANJangada MinesN/AGBX 1.17+11.4%N/A-21.4%£3.79MN/A-5,671.351Gap UpORMOrmonde MiningN/AN/AN/AN/A£3.54MN/A-2.506 Related Companies and Tools Related Companies Bluejay Mining Alternatives Firering Strategic Minerals Alternatives Bradda Head Lithium Alternatives Cadence Minerals Alternatives GreenRoc Mining Alternatives Aterian Alternatives Anglesey Mining Alternatives Beowulf Mining Alternatives Jangada Mines Alternatives Ormonde Mining Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CRTX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes ...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
